Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human lymphotoxin-alpha derivative
- Development stage
- Phase 2
- Lead developer
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human lymphotoxin-alpha derivative (rhLTα-Da, also known as LT28-171) is a genetically engineered variant of human lymphotoxin-alpha (LTα, TNF-beta) that is missing 27 N-terminal amino acid residues. Developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, rhLTα-Da acts as an agonist of the tumor necrosis factor receptors TNFR1 (TNFRSF1A) and TNFR2 (TNFRSF1B). It was investigated in clinical trials in China, including Phase II studies, for the treatment of advanced or metastatic cancers, particularly esophageal squamous cell carcinoma and gastric adenocarcinoma, often in combination with chemotherapy regimens such as cisplatin and 5-fluorouracil. However, its clinical development has been discontinued.
- Other names
- lymphotoxin-alpha derivativerhLTa-DarhLTα-Da
02
Targets
TNFRSF14 (Tumor necrosis factor receptor superfamily member 14)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on recombinant human lymphotoxin-alpha derivative.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human lymphotoxin-alpha derivative.